Synonym
17S FD 895, 17S FD-895, 17S-FD 895, 17SFD895, (17S)-FD-895
IUPAC/Chemical Name
(2S,3S,6S,7R,10S,E)-7,10-dihydroxy-2-((2E,4E,6R,7R)-7-hydroxy-7-((2R,3R)-3-((2R,3S)-3-methoxypentan-2-yl)oxiran-2-yl)-6-methylhepta-2,4-dien-2-yl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl acetate
InChi Key
LDCZLUDGHYDTHV-ZKAGHTCLSA-N
InChi Code
InChI=1S/C31H50O9/c1-9-24(37-8)21(5)29-30(40-29)27(35)18(2)11-10-12-19(3)28-20(4)13-14-25(38-22(6)32)31(7,36)16-15-23(33)17-26(34)39-28/h10-14,18,20-21,23-25,27-30,33,35-36H,9,15-17H2,1-8H3/b11-10+,14-13+,19-12+/t18-,20+,21-,23+,24+,25+,27-,28-,29-,30-,31-/m1/s1
SMILES Code
CC(O[C@@H](/C=C/[C@@H]([C@H](O1)/C(C)=C/C=C/[C@H]([C@H]([C@H]2O[C@@H]2[C@H](C)[C@H](CC)OC)O)C)C)[C@](O)(CC[C@H](O)CC1=O)C)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
566.73
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Chan WC, Trieger KA, La Clair JJ, Jamieson CHM, Burkart MD. Stereochemical Control of Splice Modulation in FD-895 Analogues. J Med Chem. 2023 May 25;66(10):6577-6590. doi: 10.1021/acs.jmedchem.2c01893. Epub 2023 May 8. PMID: 37155693.
2. Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 Nov 3;19(5):599-612. doi: 10.1016/j.stem.2016.08.003. Epub 2016 Aug 25. PMID: 27570067; PMCID: PMC5097015.
3. Butler MS. Remediating cancer via splicing modulation. J Med Chem. 2013 Sep 12;56(17):6573-5. doi: 10.1021/jm401289z. Epub 2013 Aug 27. PMID: 23981063.
